Biotechnology

Techseriesinsight > Blog > News > Biotechnology

June 12, 2025
PRNewswire
Biotechnology

Nona Biosciences and Visterra Partner to Advance Next-Generation Biotherapeutics for Immune-Mediated and Autoimmune Diseases

Nona Biosciences, a global biotechnology company providing integrated solutions from “Idea to IND” (I to ITM), today announced a license agreement with Visterra, Inc. to advance Visterra’s next-generation biotherapeutic pipeline for immune-mediated...

June 11, 2025
PRNewswire
Biotechnology

TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient

TC BioPharm (Holdings) PLC (NASDAQ: TCBP), a clinical-stage biotechnology company pioneering gamma delta T cell therapies for the treatment of cancer, today announced the first patient treated in Cohort B, presenting with detectable...

June 9, 2025
PRNewswire
Biotechnology

COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIES

CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its plant-derived, Type I recombinant human collagen (rhCollagen) for tissue regeneration and medical...

June 9, 2025
PRNewswire
Biotechnology

Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting

Dynavax Technologies Corporation (Nasdaq: DVAX) (“Dynavax” or the “Company”), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued the following statement reiterating to stockholders its recommendation to vote “FOR”...

June 2, 2025
PRNewswire
Biotechnology

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that Dr. Steven Quay, M.D., Ph.D., President and Chief Executive Officer,...

May 30, 2025
PRNewswire
Biotechnology

COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it...

May 30, 2025
PRNewswire
Biotechnology

Labcorp Expands Oncology Portfolio to Improve Patient Care and Advance Cancer Research

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio. The additions include new test offerings for solid tumor and...

May 29, 2025
PRNewswire
Biotechnology

Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson’s Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor

Biohaven Ltd. (NYSE: BHVN) (“Biohaven”), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies to treat a broad range of rare and common diseases,...

May 29, 2025
PRNewswire
Biotechnology

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

Immunic, Inc. (“Immunic” or the “Company”) (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the pricing...

May 28, 2025
PRNewswire
Biotechnology

Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will...